🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Valeant gets right to develop AstraZeneca's psoriasis drug

Published 09/01/2015, 02:32 AM
Updated 09/01/2015, 02:37 AM
© Reuters. Company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval
AMGN
-
AZN
-
BHC
-
4151
-

(Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE:VRX) said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.

The arrangement excludes Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co, Valeant said on Tuesday.

Valeant said it will make an up-front payment of $100 million to AstraZeneca, and additional pre-launch milestone payments of up to $170 million and sales-related milestone payments of up to $175 million following launch.

© Reuters. Company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval

Brodalumab belongs to a class of drugs called IL-17 inhibitors that work by blocking a signaling pathway that plays a key role in inducing and promoting inflammatory diseases. Psoriasis is a chronic autoimmune disease in which the growth cycle of skin cells is accelerated.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.